A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results

Transplant Proc. 2000 Mar;32(2):429-31. doi: 10.1016/s0041-1345(00)00838-1.

Authors

A Baldi¹, J Malaise, M Mourad, J P Squifflet

Affiliation

¹ Department of Renal Transplantation, Catholic University of Louvain Medical School, Brussels, Belgium.

PMID: 10715467
DOI: 10.1016/s0041-1345(00)00838-1

No abstract available

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial

MeSH terms

Actuarial Analysis
Antilymphocyte Serum / adverse effects
Antilymphocyte Serum / therapeutic use*
Disease-Free Survival
Follow-Up Studies
Graft Rejection / drug therapy*
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology
Kidney Transplantation / mortality
Kidney Transplantation / physiology*
Muromonab-CD3 / adverse effects
Muromonab-CD3 / therapeutic use*
Prospective Studies
Survival Rate
Time Factors

Substances

Antilymphocyte Serum
Immunosuppressive Agents
Muromonab-CD3